

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
30 November 2023 (30.11.2023)



(10) International Publication Number
WO 2023/230222 A1

(51) International Patent Classification:

A61K 31/40 (2006.01) A61K 45/06 (2006.01)
A61K 31/506 (2006.01) A61P 35/00 (2006.01)
A61K 31/519 (2006.01) G01N 33/50 (2006.01)

(21) International Application Number:

PCT/US2023/023520

(22) International Filing Date:

25 May 2023 (25.05.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/345,843	25 May 2022 (25.05.2022)	US
63/411,633	30 September 2022 (30.09.2022)	US
63/426,737	19 November 2022 (19.11.2022)	US
63/430,194	05 December 2022 (05.12.2022)	US
63/446,760	17 February 2023 (17.02.2023)	US

(71) Applicants: **SERMONIX PHARMACEUTICALS, INC.**
[US/US]; 250 East Broad Street, Suite 250, Columbus, OH

43215 (US). **ELI LILLY AND COMPANY** [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US).

(72) Inventors: **PORTMAN, David, J.**; c/o Sermonix Pharmaceuticals, Inc., 250 East Broad Street, Suite 250, Columbus, OH 43215 (US). **PLOURDE, Paul**; c/o Sermonix Pharmaceuticals, Inc., 250 East Broad Street, Suite 250, Columbus, OH 43215 (US). **JENKINS, Simon**; c/o Sermonix Pharmaceuticals, Inc., 250 East Broad Street, Suite 250, Columbus, OH 43215 (US).

(74) Agent: **BECKER, Daniel, M.** et al.; Fenwick & West LLP, 801 California Street, Mountain View, CA 94041 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,

(54) Title: LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR




FIG. 1

(57) Abstract: Methods for reducing the progression of ER+ breast cancer in a patient are provided, the methods comprising administering to the patient an effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof and an effective amount of a CDK4/6 inhibitor (CDK4/6i), wherein the breast cancer: (i) is estrogen receptor positive (ER+); (ii) has at least one gain of function missense mutation within the ligand binding domain (LBD) of the Estrogen Receptor 1 (*ESR1*) gene; and (iii) has progressed during prior CDK4/6 inhibitor therapy and/or has an oncogenic mutation in a gene other than *ESR1*.

[Continued on next page]

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*